Hikma narrows 2026 operating profit outlook to $740 million-$760 million

• Hikma Pharmaceuticals narrowed its 2026 operating profit forecast to $740 million-$760 million from $720 million-$770 million.
• Group revenue growth guidance remains at 2%-4%, with year-to-date performance in line with expectations.
• Branded revenue growth guidance increased to around 10% from 6%-8%, supported by strong demand.
• Branded core operating margin is forecast near 27%, up from around 25%, reflecting a strong product mix despite increased marketing spending.
• Injectables revenue is now expected to remain broadly flat rather than grow by low single digits; core operating margin guidance remains 27%-28%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hikma Pharmaceuticals plc published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.